Search

Displaying results 741 - 750 of 5758 in total
  1. Drug

    TM30339

    go.drugbank.com/drugs/DB05085
    Experimental

    TM30339 works through the same receptor as the natural satiety hormone, Pancreatic Polypeptide (PP), but TM30339 has improved properties compared with PP. … TM30339 is an analogue of the natural hormone Pancreatic Polypeptide (PP), which is released in connection with meals.

  2. Drug

    Lenalidomide

    go.drugbank.com/drugs/DB00480
    ApprovedInvestigational

    [A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal

    Categories: P-glycoprotein substrates
  3. Drug

    Radium Ra 223 dichloride

    go.drugbank.com/drugs/DB08913
    ApprovedInvestigational

    Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant.

  4. Drug

    Nalmefene

    go.drugbank.com/drugs/DB06230
    ApprovedInvestigationalWithdrawn

    [L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Regdanvimab

    go.drugbank.com/drugs/DB16405
    ApprovedWithdrawn

    [A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130]

  6. Drug

    Lufotrelvir

    go.drugbank.com/drugs/DB16514
    Investigational

    Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its anti-viral effects[L31718]. … Phase 1b studies are also exploring the safety and tolerability of PF-07304814 in COVID-19 patients who are hospitalized (NCT04535167).

  7. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. Bruton's tyrosine kinase plays a role in B cell r...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Donanemab

    go.drugbank.com/drugs/DB16647
    ApprovedInvestigational

    Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (Aβ), [L50978] which is found in the brain amyloid plaques that

  9. Drug

    Tovorafenib

    go.drugbank.com/drugs/DB15266
    ApprovedInvestigational

    Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, wi...

    Synonyms: 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-, 6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamideCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 Inducers
  10. Drug

    Vecabrutinib

    go.drugbank.com/drugs/DB16657
    Investigational

    Vecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers).